1
|
Molina R, Santabarbara P, Filella X, Mengual P, Ballesta AM, Balague A. Relationship of CA 125 and CA 19.9 with lung carcinoma histological subtype: Preliminary study. Int J Biol Markers 2018; 4:215-20. [PMID: 2560789 DOI: 10.1177/172460088900400406] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The aim of this work was to study the possible utility of simultaneous determination of CA 125 and CA 19.9 in patients with lung cancer. Serum levels of both markers were studied in 87 patients without metastases (Mo), 72 patients with distant metastases (MT) and 15 cases without clinical evidence of disease after primary treatment (NED). Sitxty-five tumors were epidermoid, 34 were adenocarcinomas, 24 were cell undifferentiated carcinomas and 51 were small-cell carcinomas. Sera from 75 healthy subjects and 20 patients with benign lung disease were used as controls. The cutoff values used were 35 and 37 U/ml for CA 125 and CA 19.9, respectively. CA 125 and CA 19.9 serum levels were within normal limits in all control patients. In NED patients these markers were not elevated, except in one with chronic liver disease who showed elevated CA 19.9 (76 U/ml). Twenty-five percent of Mo lung cancer patients and 40.3% of MT cases had CA 19.9 over 37 U/ml. Abnormally high levels of CA 125 were found in 18.7% and 22.9% of Mo and MT patients, respectively. Sixty percent of patients with large cell undifferentiated carcinoma had elevated CA 125 (mean 176 U/ml) compared to 15.4% of patients with all other histological types of tumors combined (54.3 U/ml, p< 0.01). CA 19.9 serum levels were also more often elevated in patients with large cell undifferentiated carcinomas (50%, 7/14 cases) than in other histological types (30%, 36/120 patients), but the difference was not statistically significant. There were no differences in CA 125 and CA 19.9 serum levels in relation to location of metastatic disease including liver. Although the sensitivity of CA 125 and CA 19.9 in lung cancer is low, they may be useful as serum markers of recurrent disease in the follow-up of patients with large cell carcinoma.
Collapse
Affiliation(s)
- R Molina
- Clinical Biochemistry Department (Unit for Cancer Research), Hospital Clinic, University of Barcelona, Spain
| | | | | | | | | | | |
Collapse
|
2
|
Abstract
MCA serum levels were determined in 27 healthy subjects, 136 with benign pathology (42 breast) and in 289 patients with cancer (247 active). The last group includes 223 patients with breast cancer (96 without metastases, 89 with metastases and 38 no-evidence of disease). CEA and CA15-3 serum levels were determined in all the patients with breast diseases. The mean levels of MCA were 4.7 + 2.4 U/ml in the control group, considering less than 11 U/ml as normal. MCA values were abnormal in 15.4 % of patients with benign pathology, mainly in those with liver cirrhosis (8/20) and lung diseases (4/20). In the majority of these cases, the rise was only moderate, lower than 15 U/ml in 97.5% of patients. In malignant diseases, important increments were found in breast cancer (19.8% Mo, 77.5% M1) and ovarian cancer stages III–IV (44.4%). When we compared MCA serum levels with CA15-3 and CEA in breast pathology, a similar specificity was observed: 92.3%, 92.3% and 100% in cases with benign pathology and 92.1%, 94.7%, and 97.4% in NED patients, respectively. MCA and CA15-3 sensitivity was similar in breast cancer without metastases (19.8%) and lower for CEA (16.7%). In patients with breast cancer without metastases, we found a relation between positivity of these tumor markers and prognostic factors (tumor size, nodal involvement). The disease free interval in patients with locoregional breast cancer was shorter in cases with abnormal presurgical levels of some of the tumor markers, but only the difference from MCA was significant (p < 0.02). Inpatients with metastases the sensitivity was about 77.5%, 70% and 65.1% respectively for MCA, CA15-3 and CEA. Sensitivity using the three tumor markers was not significantly better than with only two of them
Collapse
Affiliation(s)
- R. Molina
- Laboratory of Clinical Biochemistry (Unit for Cancer Research), Barcelona - Spain
| | - X. Filella
- Laboratory of Clinical Biochemistry (Unit for Cancer Research), Barcelona - Spain
| | - P. Mengual
- Laboratory of Clinical Biochemistry (Unit for Cancer Research), Barcelona - Spain
| | - M. Prats
- Department of Surgery (Senology Unit), Barcelona - Spain
| | - G. Zanon
- Department of Obstetrics and Gynaecology, Barcelona - Spain
| | - M. Daniels
- Department of Oncology Unit School of Medicine, Hospital Clinico, Barcelona - Spain
| | - AM. Ballesta
- Laboratory of Clinical Biochemistry (Unit for Cancer Research), Barcelona - Spain
| |
Collapse
|
3
|
Valero MA, Navarro M, Garcia-Bodelon MA, Marcilla A, Morales M, Hernandez JL, Mengual P, Mas-Coma S. High risk of bacterobilia in advanced experimental chronic fasciolosis. Acta Trop 2006; 100:17-23. [PMID: 17064656 DOI: 10.1016/j.actatropica.2006.09.002] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2006] [Revised: 09/07/2006] [Accepted: 09/08/2006] [Indexed: 11/18/2022]
Abstract
Fasciolosis is recognized as an important human disease. Wistar rats experimentally infected with Fasciola hepatica were examined using data obtained in the advanced chronic state of the disease (200, 300 and 400 days post-infection, dpi). Pigment stones (PS) and bile specimens were collected. The same procedure was applied in control rats. Liver tests were determined using stored serum samples. Bacteriological bile culture revealed viable bacteria (Escherichia coli, 45% of cases, Enterococcus faecalis, 45% and Klebsiella pneumoniae, 10%). The presence of bacterobilia was associated with liver serum enzymes, including aspartate aminotransferase (AST or SGOT), alanine aminotransferase (ALT or SGPT), alkaline phosphatase (AP) and total bilirubin levels. Multivariate analysis suggested an association between bacterobilia and the following factors: duration of parasitic infection and intensity of parasitic infection supported the impression that the obstruction caused by advanced chronic fasciolosis in the rat may be related to biliary sepsis. Extrapolation to human infection in fasciolosis hyperendemic areas is discussed. In conclusion, the results of the rodent model should lead to a reconsideration of treatment features in human disease, i.e. therapeutic strategies should not only include a parasitic treatment but also consider the possibility of bacterial co-infection.
Collapse
Affiliation(s)
- M A Valero
- Departamento de Parasitología, Facultad de Farmacia, Universidad de Valencia, Av Vicente Andrés Estellés s/n, 46100 Burjassot, Valencia, Spain.
| | | | | | | | | | | | | | | |
Collapse
|
4
|
Huertas AJ, Iriarte P, Mengual P. [Sensitization to kiwi skin]. Med Clin (Barc) 1998; 111:518-9. [PMID: 9859074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
|
5
|
Molina R, Filella X, Bruix J, Mengual P, Bosch J, Calvet X, Jo J, Ballesta AM. Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem 1991; 37:1379-83. [PMID: 1868598] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Serum concentrations of cancer antigen 125 (CA 125) were determined for 373 patients with various liver diseases: 57 with acute hepatitis, 57 with chronic hepatitis, 244 with liver cirrhosis (86 compensated and 158 decompensated), and 15 with primary liver cancer. The antigen was measured simultaneously in the serum and ascitic fluid of 46 of the patients with liver cirrhosis and sequentially in the serum and ascitic fluid of another 25 cirrhotics treated with paracentesis and (or) diuretics. Abnormal results for CA 125 were detected in sera from 4% of the patients with acute or chronic hepatitis, 60% of the patients with liver cirrhosis, and 67% of the patients with primary liver cancer. The main factor associated with abnormal serum concentrations of this antigen was the presence of ascites, with pathological CA 125 values in 94% of patients with ascites without jaundice (mean 566 +/- 528 arb. units/mL), compared with only 40% of patients with jaundice and without ascites (mean 40.1 +/- 28.5 arb. units/mL) (P less than 0.001). High concentrations of CA 125 were mainly associated with spontaneous bacterial peritonitis. The serum concentration of CA 125 decreased after treatment with paracentesis, but increased in patients treated with diuretics rather than paracentesis. The release of this antigen in liver cirrhosis appears to be independent of the liver disorder and, rather, results from peritoneal synthesis of this antigen.
Collapse
Affiliation(s)
- R Molina
- Laboratory of Clinical Biochemistry, Hospital Clinico Provincial, School of Medicine, Barcelona, Spain
| | | | | | | | | | | | | | | |
Collapse
|
6
|
Molina R, Filella X, Torres MD, Ballesta AM, Mengual P, Cases A, Balaque A. SCC antigen measured in malignant and nonmalignant diseases. Clin Chem 1990; 36:251-4. [PMID: 2302769] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
SCC antigen was measured in the serum of 214 patients with benign diseases and in 251 patients with various cancers. With 2.5 micrograms/L as the upper normal limit for serum, values were positive in 2.9% of 69 healthy subjects (I), 29.0% of 214 patients with benign pathologies (II), and 41% of 217 patients with active cancer (III). The highest values in group II were for patients in renal failure (64%) or with lung diseases (40%) or head-and-neck diseases (21.2%). Specificity of SCC increased (91.1%) when we excluded patients in renal failure or with creatinine values greater than 133 mumol/L. In group III, SCC values were abnormal in 57.7% of patients with squamous cell carcinoma, but in only 9.3% of those with other histological types (P less than 0.001). In squamous cell carcinoma of the lung, cervix, or head and neck, SCC values were related to tumor stage, values being highest in patients with metastases.
Collapse
Affiliation(s)
- R Molina
- Laboratory of Clinical Biochemistry (Unit for Cancer Research), Hospital Clinico y Provincial, Medical School, Barcelona, Spain
| | | | | | | | | | | | | |
Collapse
|
7
|
Abstract
Abstract
SCC antigen was measured in the serum of 214 patients with benign diseases and in 251 patients with various cancers. With 2.5 micrograms/L as the upper normal limit for serum, values were positive in 2.9% of 69 healthy subjects (I), 29.0% of 214 patients with benign pathologies (II), and 41% of 217 patients with active cancer (III). The highest values in group II were for patients in renal failure (64%) or with lung diseases (40%) or head-and-neck diseases (21.2%). Specificity of SCC increased (91.1%) when we excluded patients in renal failure or with creatinine values greater than 133 mumol/L. In group III, SCC values were abnormal in 57.7% of patients with squamous cell carcinoma, but in only 9.3% of those with other histological types (P less than 0.001). In squamous cell carcinoma of the lung, cervix, or head and neck, SCC values were related to tumor stage, values being highest in patients with metastases.
Collapse
Affiliation(s)
- R Molina
- Laboratory of Clinical Biochemistry (Unit for Cancer Research), Hospital Clinico y Provincial, Medical School, Barcelona, Spain
| | - X Filella
- Laboratory of Clinical Biochemistry (Unit for Cancer Research), Hospital Clinico y Provincial, Medical School, Barcelona, Spain
| | - M D Torres
- Laboratory of Clinical Biochemistry (Unit for Cancer Research), Hospital Clinico y Provincial, Medical School, Barcelona, Spain
| | - A M Ballesta
- Laboratory of Clinical Biochemistry (Unit for Cancer Research), Hospital Clinico y Provincial, Medical School, Barcelona, Spain
| | - P Mengual
- Laboratory of Clinical Biochemistry (Unit for Cancer Research), Hospital Clinico y Provincial, Medical School, Barcelona, Spain
| | - A Cases
- Laboratory of Clinical Biochemistry (Unit for Cancer Research), Hospital Clinico y Provincial, Medical School, Barcelona, Spain
| | - A Balaque
- Laboratory of Clinical Biochemistry (Unit for Cancer Research), Hospital Clinico y Provincial, Medical School, Barcelona, Spain
| |
Collapse
|
8
|
Molina R, Filella X, Mengual P, Prats M, Zanon G, Daniels M, Ballesta AM. MCA in patients with breast cancer: correlation with CEA and CA15-3. Int J Biol Markers 1990; 5:14-21. [PMID: 2230347] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
MCA serum levels were determined in 27 healthy subjects, 136 with benign pathology (42 breast) and in 289 patients with cancer (247 active). The last group includes 223 patients with breast cancer (96 without metastases, 89 with metastases and 38 no-evidence of disease). CEA and CA15-3 serum levels were determined in all the patients with breast diseases. The mean levels of MCA were 4.7 + 2.4 U/ml in the control group, considering less than 11 U/ml as normal. MCA values were abnormal in 15.4% of patients with benign pathology, mainly in those with liver cirrhosis (8/20) and lung diseases (4/20). In the majority of these cases, the rise was only moderate, lower than 15 U/ml in 97.5% of patients. In malignant diseases, important increments were found in breast cancer (19.8% Mo, 77.5% M1) and ovarian cancer stages III-IV (44.4%). When we compared MCA serum levels with CA15-3 and CEA in breast pathology, a similar specificity was observed: 92.3%, 92.3% and 100% in cases with benign pathology and 92.1%, 94.7%, and 97.4% in NED patients, respectively. MCA and CA15-3 sensitivity was similar in breast cancer without metastases (19.8%) and lower for CEA (16.7%). In patients with breast cancer without metastases, we found a relation between positivity of these tumor markers and prognostic factors (tumor size, nodal involvement). The disease free interval in patients with locoregional breast cancer was shorter in cases with abnormal presurgical levels of some of the tumor markers, but only the difference from MCA was significant (p less than 0.02).(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- R Molina
- Laboratory of Clinical Biochemistry (Unit for Cancer Research), School of Medicine, Hospital Clinico, Barcelona, Spain
| | | | | | | | | | | | | |
Collapse
|
9
|
Martínez Comín L, Navarro Izquierdo A, Mengual P, Arbues J, Baringo T, Solsona F. [Diagnosis of intrahepatic expansive processes. Gammagraphy and echography]. Rev Esp Enferm Apar Dig 1981; 60:579-88. [PMID: 7330423] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
|